Tech Transfer Roundup: MD Anderson, NCI Lead Cancer Alliances
MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.
You may also be interested in...
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.